Form 4: Xeris Biopharma Holdings CFO Sells Shares

Xeris Biopharma Holdings, Inc. (XERS) Chief Financial Officer, Steven Pieper, reported transactions involving the sale of company stock.

Summary

• Steven Pieper, Chief Financial Officer of Xeris Biopharma Holdings, Inc., engaged in stock transactions on July 6, 2026, and July 7, 2026.
• On July 6, 2026, 17,400 shares of common stock were sold at a price of $8.50 per share.
• On July 7, 2026, an additional 27,600 shares were sold at a weighted average price of $8.52, with individual sales ranging from $8.50 to $8.60.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on August 18, 2025.
• Following these sales, Mr. Pieper beneficially owns 1,366,053 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the CFO's sale of a substantial number of shares, despite the pre-planned nature of the transactions.

Negatives

• The Chief Financial Officer sold a significant number of shares (45,000 total) over two days.

Future Outlook

No forward-looking statements or guidance are present in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings, such as this one from Xeris Biopharma Holdings, are standard disclosures for insider transactions. While sales by executives can sometimes be interpreted negatively, the explicit mention of a Rule 10b5-1 trading plan suggests these sales were pre-planned and not necessarily indicative of a negative outlook on the company's future performance.

Stakeholder Impact

• Shareholders may view the CFO's sale of stock with concern, potentially impacting investor sentiment, even though the sales were conducted under a pre-arranged trading plan.

Key Dates

Recommendation

The filing indicates a pre-planned sale of stock by the CFO under a Rule 10b5-1 plan. While insider selling can be a negative signal, the structured nature of the sale suggests it may not reflect a change in the executive's fundamental view of the company. Therefore, a 'hold' recommendation is appropriate pending further information or performance indicators.

Keywords

Form 4, Insider Trading, Stock Sale, Xeris Biopharma Holdings, XERS, CFO, Rule 10b5-1